Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) filed an application for a new U.S. Patent that refines the use of fluorescent microscopy to increase the accuracy, sensitivity and specificity of the CyPath® diagnostic assay for lung cancer.

"This patent is based on a proprietary solid-state, diode-based light source for fluorescent microscopy that will improve our ability to differentiate between cancer cells and the so-called debris and artifacts found at the cellular level in tissue and body samples," Biomoda President John Cousins said. "By stabilizing the excitation mechanism and reducing variations in the way we measure photonic emissions from cells, this invention simultaneously increases our accuracy and reduces costs associated with the current technology."

The porphyrin-based CyPath® assay binds to cancer cells and causes them to fluoresce under specific frequencies of light. The pilot clinical study concluded in March 2011 demonstrated that CyPath® is a significant new biomarker for lung cancer.

"This technical breakthrough is the result of our optimization studies to improve the sensitivity and specificity of our assay," Biomoda CEO Maria Zannes said. "Biomoda's intellectual property is our core asset, and we expect to continue to build our patent portfolio with innovations like this one."

Biomoda has four U.S. patents and foreign patent rights in Europe, Canada, Japan, Mexico and Australia.

About Biomoda

Biomoda (www.biomoda.com) is focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder and oral cancers are targeted for development.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results. Actual results could differ materially due to a variety of factors, which are described from time to time in the Company's filings with the Securities and Exchange Commission, including "Risk Factors" outlined in the Company's Annual Report on Form 10-K filed with the SEC on March 15, 2011. Forward-looking statements are made as of the date of this press release and are subject to change without notice.

Biomoda, Inc.
Julie Anne Overton, 505-577-0918